

Index

- acupuncture 110
- age at menopause 1
 - determinants 3–4
- ageing
 - population 1–2
 - reproductive, stages 6–8
 - skin 47
- alcohol intake 21, 24, 46
- alendronate 123, 124, 125
- Alzheimer's disease 25, 89–90
- anastrozole 162
- androgens 5–6
 - serum testing 37
 - therapy 63–4, 78–9, 89, 138
- android body shape 43
- androstenedione 5–6
- anticoagulation 146–7
- anti-epileptic drugs 151
- anti-müllerian hormone (AMH) 4–5, 136
- antioxidants 44
- anxiety 102
- aromatase inhibitors 162, 163
- arthralgia 28
- arthritis 28
- aspirin 47–8
- assessment, patient 31–40
- asthma 153–4
- atherosclerosis 18, 87
- atrial fibrillation 125
- attitudes, women's 34
- aura, migraine 26
- autoimmune disease 133, 149

- barrier contraceptive methods 58–9
- bazedoxifene 69, 126–7
- beta-blockers 102

- bilateral oophorectomy 134, 151, 166
- bio-identical hormone therapy 79–80, 109–10
- bisphosphonates 123–5, 162–3
- black cohosh 107–8
- bleeding, vaginal
 - abnormal, HRT users 40
 - heavy menstrual bleeding 142
 - HRT users 38–40, 68, 76
 - IUCD users 56
- body mass index (BMI) 43, 115
- bone marrow transplant recipients 154–5
- bone mass
 - factors affecting 23, 24
 - peak 114
 - strategies for maximising 45, 115
- bone mineral density (BMD) 114, 115, 118
- bone turnover markers 114
- bowel cancer *see* colorectal cancer
- BRCA mutation carriers 159, 160, 166
- breast cancer 158–65
 - cardiovascular risk after 163
 - contraception 164–5
 - family history 35, 159
 - fertility 163–4
 - menopausal symptom management 160–2
 - osteoporosis management 162–3
 - previous 160–5
 - risk factors 43, 46, 158–60
 - risk in HRT users 84, 91–2, 160
 - screening 49
- breast disease, benign 159
- breast tenderness, HRT-related 74
- British Menopause Society (BMS) 31, 87–8, 122–3

- CA125 blood test 50
 calcitonin 124
 calcium
 dietary intake 44, 120
 supplements 119, 124
 cancer, previous/increased risk 157–68
 cap, contraceptive 59
 carbohydrate, dietary 43
 cardiovascular disease (CVD) 17–21
 breast cancer survivors 163
 effects of HRT 17–18, 84, 92–4
 risk screening 47–8
 safety of HRT 144–7
 window of opportunity for HRT 86–7, 93
 see also stroke
 cardiovascular risk factors 18–21
 assessment 35
 modification 42–6
 cardiovascular timing hypothesis 86–7, 93
 Cerazette 58
 Cerelle 58
 cervical cancer 48, 167
 cervical intraepithelial neoplasia (CIN) 48
 cervical screening 48–9
 chasteberry 109
 chemotherapy
 cardiovascular adverse effects 163
 childhood cancers 168
 fertility support after 138–9
 osteoporosis risk after 162
 premature ovarian insufficiency 133–4, 163–4
 childhood cancers 168
 cholesterol, serum 19–20, 145
 cholesterol desmolase deficiency 132
 Cholesterol Treatment Trialists Collaboration 48
 chromosome abnormalities 131–2
 citalopram 101
 climacteric 3
 climacteric syndrome 3
 clonidine 101
 cognition 25, 89–90
 cognitive behaviour therapy (CBT) 103, 110, 161
 coitus interruptus 59
 Colles' fractures 22
 colorectal cancer 167
 effects of HRT 91
 family history 35, 51
 screening 50–1
 combined hormonal contraception 57–8
 combined oral contraceptive pill 57–8, 137, 150, 153
 comorbid medical conditions 141–55
 complementary and alternative therapies 105–11, 138, 161
 condoms 58
 connective tissue disease 152–3
 consultation, menopause 31–2, 40–1
 contraception 53–9
 barrier methods 58–9
 breast cancer survivors 164–5
 combined hormonal 57–8
 duration of use 54–5
 long-acting reversible (LARC) 55–7
 menstrual migraine and 150
 natural methods 59
 options 55–9
 premature ovarian insufficiency 138
 progestogen-only pill 58
 copper intrauterine contraceptive devices (IUCD) 56
 coronary heart disease (CHD) 17–18, 86–7, 93
 corticosteroid therapy 115
 counselling 103, 136–7
 cultural differences, menopausal symptoms 11–12
 decision making 40–1
 dehydroepiandrosterone (DHEA) 5–6, 79, 111
 dementia 25, 89–90
 demographic change 1–2
 denosumab 127
 depot medroxyprogesterone acetate 57, 102
 depression 13
 effects of HRT 25, 89
 management 102–3
 17-20-desmolase deficiency 133
 desvenlafaxine 101, 161

- diabetes mellitus 20–1, 148
- diaphragm, contraceptive 59
- diet 43–5, 115
- diosgenin 108–9
- dong quai 108
- dual-energy x-ray absorptiometry (DXA) 114
- Duavive 126–7
- dyspareunia 62–3

- early menopause 3, 131
- embryo freezing 138–9
- endocrine diseases 148–9
- endometrial ablation 71
- endometrial biopsy 39
- endometrial cancer
 - HRT use after 166
 - risk factors 34
 - risk in HRT users 67, 96
- endometrial histology 39
- endometrial hyperplasia 39
- endometrial polyps 143
- endometriosis 71, 143
- epilepsy 150–1
- estradiol 4, 5
 - implants 70–1
 - oral vs. parenteral administration 69–70, 85–6
 - serum testing 36, 37
 - vaginal *see* vaginal estrogens
- Estring 78
- estriol 67
 - vaginal cream 61, 78
- estrogen-based therapies 66–80
 - comorbid medical conditions 141–55
 - delivery routes 69–71
 - osteoporosis 121–3
 - post hysterectomy 71
 - women with previous/high risk of cancer 157–68
 - see also* hormone replacement therapy
- estrogens
 - adverse effects 74
 - cardiovascular effects 17–18
 - conjugated (equine) 67, 69–70, 72, 84
 - doses 72
 - HRT preparations 67
 - natural 67
 - oral vs. parenteral administration 69–70, 85–6
 - synthetic 67
 - transdermal delivery 70
 - vaginal *see* vaginal estrogens
- estrone 67
- ethnic differences
 - bone mass 23
 - menopausal symptoms 11–12
- etidronate 124
- European Society of Human Reproduction and Embryology 171
- evening primrose oil 108
- Evra 57–8
- examination, physical 36
- exercise 24, 44, 103–4, 115

- factor V Leiden 146
- Faculty of Occupational Medicine 171
- Faculty of Sexual and Reproductive Healthcare (FSRH) 55, 56, 57, 58, 165
- faecal occult blood testing 51
- family history 35
- family planning, natural 59
- female sexual dysfunction 14–15, 62–4
- fertility 54
 - cancer survivors 163–4, 168
 - premature ovarian insufficiency 138–9
- fibre, dietary 43–4
- fibroids, uterine 142
- fish oil 43
- fluoxetine 101, 161
- follicle-stimulating hormone (FSH)
 - menopausal transition 4, 6
 - premenopause 4, 5
 - serum testing 36–7
 - stages of reproductive ageing 6–8
- follow-up, treatment 38
- Food and Drug Administration (FDA), US 62, 79–80
- fractures, osteoporotic 22–3, 114
- FRAX 116–18
- free androgen index 37
- functional foods 44–5

- gabapentin 102
- galactosaemia 132
- gallbladder disease 151–2
- Gardasil 49
- gastrointestinal conditions 151–2
- gastrointestinal upset, HRT-related 74
- genitourinary syndrome of the
 - menopause *see* urogenital atrophy
- gingko biloba 108
- ginseng 108
- glucocorticoid therapy 115
- glycaemic index 43
- gonadotrophin-releasing hormone (GnRH) 4
 - agonists 142, 164
- gonadotrophins 4
- Greene Climacteric Scale 33
- gynaecological cancers 165–7
- gynaecological disorders 142–4
- gynoid body shape 43

- health promotion 42–51
- Heart and Oestrogen/progestin Replacement Study (HERS) 148, 151
- heavy menstrual bleeding 142
- herbal remedies 107–9
- high-density lipoprotein (HDL)
 - cholesterol 20, 145
- hip fractures 22–3
- homoeopathy 110
- hormone assays 36–7
- hormone replacement therapy (HRT)
 - 66–80, 82–97
 - adverse effects 73–6
 - after endometrial ablation 71
 - after hysterectomy 71
 - alternative terms 66
 - avoidance by some women 105–6
 - benefits 82–3, 87–91
 - bio-identical hormones 79–80, 109–10
 - bleeding issues 38–40, 68, 76
 - breast cancer risk 84, 91–2, 160
 - breast cancer survivors 161–2
 - cardiovascular effects 17–18, 84, 92–4
 - cardiovascular timing hypothesis 86–7, 93
 - clinical practice post-WHI 85–7
 - cognitive effects 25, 89–90
 - colorectal cancer and 91
 - combined 67
 - comorbid medical conditions 141–55
 - components 67–9
 - continuous combined (no bleed) 67–8, 73, 75
 - cyclical (sequential) 67, 73
 - decision making 40–1
 - dosage 72
 - duration 76–8
 - follow-up 38
 - lipid profiles and 20
 - long cycle 73, 75
 - for menopausal symptoms 76–7, 87–91
 - migraines and 26
 - Mirena intrauterine system 56, 69
 - mood and depressive symptoms 25, 89
 - musculoskeletal effects 90
 - oral vs. parenteral route 69–70, 85–6
 - osteoporosis 77, 90–1, 121–3
 - parenteral route 69–71
 - premature ovarian insufficiency 77, 137–8
 - prescribing 72–3
 - risks 82, 91–7
 - routes of delivery 69–71, 85–6
 - starting 72
 - stopping 77–8
 - switching to continuous combined 73
 - WHI findings 83, 84–5
 - women with previous/at high risk of cancer 157–68
- hot flushes 12, 100
 - non-hormonal therapies 101, 102
 - see also* vasomotor symptoms
- HRT *see* hormone replacement therapy
- human papillomavirus (HPV) 48–9
- Hyalofemme 61
- 17-alpha-hydroxylase deficiency 132
- hyperlipidaemia 19–20, 145
- hypertension 19, 144–5
- hyperthyroidism 149
- hypothyroidism 149
- hysterectomy 71, 134, 167
- hysteroscopy 39

- ibandronate 123, 124
- infections, ovarian 134
- inflammatory bowel disease 152
- inhibin B 4
- INTERHEART study 18, 19, 42–3
- International Menopause Society 171
- intrauterine contraceptive devices (IUCD), copper 56
- intrauterine systems, levonorgestrel-releasing 56–7, 69, 142
- investigations 36–40
- in vitro* fertilisation (IVF) 138
- isoflavones 106–7

- Jaydess 56, 57
- joint pain 28

- letrozole 162
- levonorgestrel 68
- levonorgestrel-releasing intrauterine systems 56–7, 69, 142
- levothyroxine 149
- libido *see* sexual desire
- life coaching 103
- lifestyle, healthy 42–7, 138
- lignans 106
- lipid profile, serum 19–20, 145
- liquorice root 109
- liver disease 152
- long-acting reversible contraception (LARC) 55–7
- long-term health conditions 16–28
- low-density lipoprotein (LDL) cholesterol 19–20, 145
- lubricants, vaginal 61, 109
- lung cancer 96–7
- luteinising hormone (LH) 4, 5, 36–7

- magnetism 110
- malignancy, previous/increased risk 157–68
- mammography 49
- medical history 34–5
- medroxyprogesterone acetate, depot 57, 102
- megestrol acetate 102
- melanoma, malignant 167
- memory 25, 89–90

- menopause
 - defined 2
 - early 3, 131
 - induced/iatrogenic 3, 133–4
 - premature *see* premature ovarian insufficiency
 - staging 6–8
- Menopause Rating Scale 33
- Menopause Specific Quality of Life Questionnaire 33
- menopause transition
 - definitions 2, 3
 - ovarian function 4–6
 - stages 6–8
 - see also* perimenopause
- menstrual cycle 4, 5, 6–8
- menstrual history 34
- metabolic syndrome 21
- migraine 25–6, 150
- mindfulness 103
- Mirena intrauterine system 56, 69
- mood changes 13
 - effects of HRT 25, 89
 - treatment 102–3
- mumps 134
- musculoskeletal effects, HRT 90
- myocardial infarction 47–8, 93

- National Health and Social Life survey, US 62
- National Institute for Health and Care Excellence (NICE)
 - breast cancer survivors 160–1, 162
 - cardiovascular effects of HRT 93, 94
 - complementary and alternative therapies 107
 - contraception 54, 55
 - menopause guideline 83, 171
 - osteoporosis 91, 115
 - other benefits of HRT 89, 90
 - ovarian cancer 49–50
 - testosterone therapy 79, 89
 - vaginal estrogens 61, 78, 88
 - vasomotor symptoms 88, 101
- National Osteoporosis Guideline Group (NOGG) 116–18
- National Osteoporosis Society (NOS) 122–3

- natural family planning 59
 neurological diseases 150–1
 Nexplanon 57
 NICE *see* National Institute for Health
 and Care Excellence
 night sweats 12, 100
 nonoxynol-9 59
 norethisterone 68, 102
 Nurses' Health Study 43, 46, 147
 NuvaRing 58
- obesity 20, 43
 central (abdominal) 20, 21, 43, 147
 colorectal cancer risk 51
 HRT management 147
 omega-3 fatty acids 43
 oocytes 4
 cryopreservation 138–9, 168
 IVF using donor 138
 oophorectomy, bilateral 134, 151, 166
 oral contraceptive pill, combined *see*
 combined oral contraceptive pill
 oral route, HRT 69–70, 85–6
 organ transplant recipients 154–5
 ospemifene 62
 osteoarthritis 28
 osteonecrosis, jaw 125
 osteopenia 114, 121
 osteoporosis 21–4, 113–27
 breast cancer survivors 162–3
 diagnosis 114–15
 estrogen-based treatments 77, 90–1,
 121–3
 fractures 22–3, 114
 lifetime risk 114
 management 23–4, 77, 119–21
 non-estrogen-based treatments
 123–7
 predisposing medical conditions 148,
 151, 152, 153, 154–5
 prevention 90–1, 115
 risk assessment 35, 116–18
 risk factors 23–4, 116
 otosclerosis 154
 ovarian cancer
 family history 35, 166
 HRT-related risk 95–6
 HRT use after 165–6
 risk factors 50
 screening 49–50
 ovarian function 4–6
 ovarian reserve, assessing 136
 ovarian tissue, cryopreservation 139
 overactive bladder 27
 Ovestin 78
- palpitations 102
 panic attacks 102
 parathyroid hormone peptides 124, 127
 Parkinson's disease 151
 paroxetine 101, 161
 pelvic floor exercises 46
 perimenopause
 contraceptive options 55–9
 defined 2
 duration of contraception 54–5
 stages 6–8
 see also menopause transition
 physical activity 24, 44, 103–4, 115
 phytoestrogens 106–7
 polycystic ovary syndrome (PCOS)
 143–4
 population risk 42–3
 postmenopause
 definition 3
 stages 7, 8
 pregnancy, older women 54
 Premarin 67, 84
 premature ovarian insufficiency (POI)
 130–9
 aetiology 131–4
 breast cancer survivors 163–4
 childhood cancer survivors 168
 definition 3, 131
 long-term health effects 135
 management 77, 136–9
 osteoporosis prevention 122
 presentation and assessment 135–6
 Premature Ovarian Insufficiency
 Register 136
 premenopause 3
 processed meat 43, 51
 progesterone 4, 5
 micronised, for HRT 68, 86
 natural 108–9
 safety profile 86, 94, 95

- progestogen-only contraceptive pill 58
- progestogen-only injectable
 - contraceptives 57
- progestogen-releasing intrauterine
 - systems 56–7, 69, 142
- progestogens
 - adverse effects 74–5
 - breast cancer survivors 161
 - classification of synthetic 68
 - intolerance 75
 - migraines and 26
 - safety profile 86, 94, 95
 - subdermal contraceptive implants 57
 - transdermal delivery 70
 - used in HRT 67–9
 - for vasomotor symptoms 102
- prolapse, pelvic organ 28, 46
- propranolol 102
- psychological support 136–7
- psychological symptoms 11, 13
 - breast cancer survivors 161
 - management 102–3
- psychological therapies 103
- psychosexual therapy 63

- Qlaira 58
- quantitative ultrasound (QUS) 115

- radiotherapy
 - cardiovascular adverse effects 163
 - childhood cancers 168
 - fertility support after 138–9
 - premature ovarian insufficiency 133–4
- raloxifene
 - comorbid medical conditions 145, 147, 149, 153
 - osteoporosis management 124, 126
- Raloxifene Use for The Heart (RUTH)
 - study 126, 145
- RANKL 127
- red meat 43, 51
- reflexology 110
- Regelle 61, 109
- renal failure 154
- Replens 61, 109
- reproductive ageing, stages of 6–8
- respiratory problems 153–4

- rheumatoid arthritis 152
- risedronate 123, 124

- sage 108
- Sayana Press 56, 57
- screening 47–51
- selective estrogen receptor modulators (SERMs) 62, 69, 126–7
- selective progesterone receptor
 - modulators 142
- selective serotonin reuptake inhibitors (SSRIs) 101
- serotonin and noradrenaline reuptake
 - inhibitors (SNRIs) 101, 161
- sex hormone binding globulin (SHBG) 37, 70, 79
- sexual desire, lack of 6, 63, 138
- sexual dysfunction, female 14–15, 62–4
- sexual function, effects of HRT 88–9
- sexual health 53–4, 59–64
- sexually transmitted infections (STIs) 57, 59
- skin ageing, sun induced 47
- smoking 19, 24, 45–6
- sodium intake, dietary 44
- spermicide 59
- Stages of Reproductive Aging
 - Workshop (STRAW) staging
 - system 6–8
- statins 20, 48, 145
- stellate ganglion block 111
- steroid therapy 115
- St John's wort 109
- stress incontinence 27
- stroke 17
 - HRT-related risk 84, 85, 86–7, 94–5
 - migraine and risk 26, 150
 - risk factors *see* cardiovascular risk factors
- strontium ranelate 124, 126
- sun exposure 47, 120
- sunscreen 47
- surgery, HRT and 147
- surgical menopause 3, 134
 - sexual function after 63
 - testosterone therapy 79
- Sylk 61, 109

- symptoms, menopausal 11–15
 - assessment 32
 - complementary and alternative therapies 105–11
 - estrogen-based therapies 76–7, 87–91
 - non-estrogen-based therapies 100–4
 - score chart 33
 - women at high risk of/with breast cancer 160–2
- systemic lupus erythematosus (SLE) 152–3

- tachyphylaxis 71
- tamoxifen 101, 149, 161, 162, 163
- teriparatide 127
- testosterone 5–6
 - serum testing 37
 - therapy 63–4, 78–9, 89, 138
- thrombophilia
 - inherited 146
 - screen 38, 146
- thyroid disease 148–9
- thyroid hormone therapy 149
- tibolone 64, 69, 89
 - postmenopausal osteoporosis 122
 - safety 95, 147
- tissue-selective estrogen complex 69
- transdermal contraceptive patch (Evra) 57–8
- transdermal HRT systems 70
 - doses 72
 - risks 70, 85–6, 94, 95
- transplant recipients 154–5
- transvaginal ultrasound (or sonography) (TVS) 39, 50
- triglycerides 20, 145
- T score 114
- tuberculosis 134

- UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 50
- UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) 55, 165
- ulipristal acetate 142
- urgency, urinary 27
- urge urinary incontinence 27

- urinary incontinence 26–8
- urogenital atrophy 59–62
 - breast cancer survivors 161
 - symptoms 14, 60
 - treatment 60–2, 78, 88
- uterine artery embolisation 134

- Vagifem 78
- vaginal dryness 61
- vaginal estrogens
 - breast cancer survivors 161
 - pelvic organ prolapse 28
 - safety profile 88
 - urinary incontinence 27–8
 - urogenital atrophy 60–1, 78, 88
- vaginal moisturisers 61, 109
- vaginal ring, contraceptive 57–8
- vaginal therapies, non-hormonal 61, 109
- valerian root 109
- valvular heart disease 145
- vasomotor symptoms 11, 12
 - breast cancer survivors 161
 - complementary and alternative therapies 106–7, 108–9
 - HRT 76–7, 87–8
 - non-estrogen-based therapies 100–2
- venlafaxine 101, 161
- venous thromboembolism (VTE)
 - history 35
 - HRT-related risk 95, 146
 - route of HRT delivery and 70, 85–6
 - thrombophilia screen 38, 146
 - women at high risk 146–7, 153
- vertebral fractures 22
- vitamin B12 44
- vitamin D 119–21
 - dietary intake 44, 120
 - supplements 119, 121, 124
- vitamins 44, 45
- vulvovaginal atrophy *see* urogenital atrophy

- waist circumference 21, 43
- weight gain, HRT-related 74–5
- WHI *see* Women's Health Initiative
- window of opportunity theory, HRT 86–7, 93

- Women's Health Initiative (WHI) 83, 84–5
 - breast cancer 91
 - cardiovascular effects of HRT 18, 84, 93, 94
 - cognitive effects of HRT 25
 - colorectal cancer 91
 - gallbladder disease 151
 - lung cancer 96–7
 - malignant melanoma 167
 - metabolic effects of HRT 148
 - ovarian cancer risk 95
 - stopping HRT 77
 - venous thromboembolism risk 146
- X chromosome abnormalities 131–2
- yam, wild 108–9
- YES 61, 109
- yoga 110
- Zoely 58
- zoledronic acid 123, 124, 125